Immunodiagnostic Systems slashes guidance as sales slump
This article was originally published in Clinica
Executive Summary
UK diagnostic specialist Immunodiagnostic Systems (IDS) has reduced its guidance, leading to at least one analyst reclassifying its stock as “sell.” The company is now expecting sales for the fiscal year ending March 2015 of £45-47m ($73-76m), 12-15% below expectations, noted Canaccord Genuity analyst Julie Simmonds, who has downgraded the firm.